Drug news
NICE rejects breast cancer treatment
The National Institute for Health and Care Excellence (NICE) in draft guidance has found that Halaven (eribulin) from Eisai is not cost effective for use in patients with locally advanced or secondary breast cancer after only one chemotherapy regimen. NICE commented that although Halaven increases overall survival by an average of 4.6 months compared to capecitabine, there was uncertainty about the survival data.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.